ViaDerma, Inc. (VDRM)
ViaDerma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Las Vegas, NV, US. The stock last traded at $0.00, up 20.00% on the session, giving a market capitalisation of $740,226. On trailing twelve-month figures it carries a trailing P/E of 172.45, a net margin of 0.7%. Its beta of 0.20 implies it has historically moved less than the broad market.
ViaDerma, Inc., a specialty pharmaceutical enterprise based in the United States, focuses on both the development and commercialization of pharmaceutical products. It also licenses its proprietary technology to other companies within the pharmaceutical sector, addressing various therapeutic areas. The company's primary offering is Vitastem, a topical antibiotic containing tetracycline, effective for treating a broad spectrum of ailments such as cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Beyond its established products, ViaDerma is dedicated to expanding its pipeline, with ongoing development in fields including advanced topical antibiotics, antifungal treatments for toenails, diabetic amputation recovery, general acne, psoriasis, eczema, burn care, anti-aging and wrinkle-reducing formulations, medical cannabis applications, male pattern baldness, skin cancer, erectile dysfunction, and pain management. Established in 2007, the company operated as Décor Products International, Inc. until its renaming to ViaDerma, Inc. in May 2014. Its corporate operations are directed from Marina Del Rey, California.
ViaDerma, Inc. is most often compared with the following Healthcare names: